Filtered By:
Condition: Obesity
Drug: Insulin

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 476 results found since Jan 2013.

Association of Hypoglycemic Treatment Regimens on Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A Substudy of the SCOUT Trial.
CONCLUSIONSIn obese patients with type 2 diabetes and high risk of cardiovascular disease, monotherapy with metformin or diet-only treatment were associated with lower risk of cardiovascular events than treatment with insulin. PMID: 24089540 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 2, 2013 Category: Endocrinology Authors: Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C Tags: Diabetes Care Source Type: research

Gender‐Specific Effects of Oral Hypoglycemic Agents on Cancer Risk in Type 2 Diabetes Mellitus
ConclusionsOral insulin sensitizers, particularly thiazolidinedione, are associated with decreased malignancy risk in women with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - November 6, 2013 Category: Endocrinology Authors: Grace E. Ching Sun, Brian J. Wells, Kathleen Yip, Robert Zimmerman, Derek Raghavan, Michael W. Kattan, Sangeeta R. Kashyap Tags: Original Paper Source Type: research

Gender‐specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus
ConclusionsOral insulin sensitizers, particularly thiazolidinedione, are associated with decreased malignancy risk in women with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - December 5, 2013 Category: Endocrinology Authors: G. E. C. Sun, B. J. Wells, K. Yip, R. Zimmerman, D. Raghavan, M. W. Kattan, S. R. Kashyap Tags: ORIGINAL ARTICLE Source Type: research

Metabolic Syndrome and Non-Cardiac Vascular Diseases: an Update from Human Studies.
Abstract The metabolic syndrome (MetS) is characterized by a cluster of risk factors including central obesity, hypertension, dyslipidemia and insulin resistance, The MetS is associated with an increased risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Several international organizations have defined MetS using different diagnostic criteria that produced discrepancies in the results of previous studies, thus leading to the latest Joint Interim Societies (JIS) MetS definition. Other risk factors than the diagnostic criteria that have been associated with MetS include lipid abnormalities, u...
Source: Current Pharmaceutical Design - December 5, 2013 Category: Drugs & Pharmacology Authors: Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

Relationship of obesity and insulin resistance with the cerebrovascular reactivity: a case control study
Conclusions: We found a diminished vasomotor reactivity in individuals with obesity which was not explained by the presence of insulin resistance.
Source: Cardiovascular Diabetology - January 3, 2014 Category: Cardiology Authors: Marcela Rodríguez-FloresCarlos Cantú-BritoEduardo García-GarcíaClaudia Cano-Nigenda Source Type: research

Adiponectin as a routine clinical biomarker.
Abstract Adiponectin is a protein synthesized and secreted predominantly by adipocytes into the peripheral blood. However, circulating adiponectin level is inversely related with body weight, especially visceral fat accumulation. The mechanism of this paradoxical relation remains obscure. Low circulating adiponectin concentrations (hypoadiponectinemia; <4 μg/mL) are associated with a variety of diseases, including dysmetabolism (type 2 diabetes, insulin resistance, hypertension, dyslipidemia, metabolic syndrome, hyperuricemia), atherosclerosis (coronary artery disease, stroke, peripheral artery disease), slee...
Source: Clin Med Res - January 1, 2014 Category: Research Authors: Kishida K, Funahashi T, Shimomura I Tags: Best Pract Res Clin Endocrinol Metab Source Type: research

Modeling Effects of SGLT‐2 Inhibitor Dapagliflozin Treatment vs. Standard Diabetes Therapy on Cardiovascular and Microvascular Outcomes
ConclusionsBased on these simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.
Source: Diabetes, Obesity and Metabolism - January 20, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H.L. Grossman, M. Cohen Tags: Original Paper Source Type: research

Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
ConclusionsOn the basis of simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.
Source: Diabetes, Obesity and Metabolism - February 19, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H. L. Grossman, M. Cohen Tags: ORIGINAL ARTICLE Source Type: research

The relationship between insulin-sensitive obesity and cardiovascular diseases in a Chinese population: Results of the REACTION study
Conclusion: Both general and abdominal obesity were associated with elevated prevalent cardiovascular diseases and 10-year CHD risk, regardless of the presence or absence of insulin resistance.
Source: International Journal of Cardiology - February 6, 2014 Category: Cardiology Authors: Jieli Lu, Yufang Bi, Tiange Wang, Weiqing Wang, Yiming Mu, Jiajun Zhao, Chao Liu, Lulu Chen, Lixin Shi, Qiang Li, Qin Wan, Shengli Wu, Guijun Qin, Tao Yang, Li Yan, Yan Liu, Guixia Wang, Zuojie Luo, Xulei Tang, Gang Chen, Yanan Huo, Zhengnan Gao, Qing Su, Tags: Original Articles Source Type: research

Associations of Pentraxin 3 with Cardiovascular Disease: The Multi‐Ethnic Study of Atherosclerosis
ConclusionsIn these apparently healthy adults, PTX3 was associated with CVD risk factors, subclinical CVD, CAC and incident coronary heart disease events independent of CRP and CVD risk factors. These results support the hypothesis that PTX3 reflects different aspects of inflammation than CRP and may provide additional insight into the development and progression of atherosclerosis.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 1, 2014 Category: Hematology Authors: Nancy Swords Jenny, Roger S. Blumenthal, Richard A. Kronmal, Jerome I. Rotter, David S. Siscovick, Bruce M. Psaty Tags: Original Article ‐ Vascular Biology Source Type: research

Genomic structure of nucleotide diversity among Lyon rat models of metabolic syndrome
Conclusions: Whole genome sequence analysis between the LH, LN, and LL strains identified the haplotype structure of these three strains and identified candidate genes with sequence variants predicted to affect gene function. This approach, merged with additional integrative genetics approaches, will likely lead to novel mechanisms underlying complex disease and provide new drug targets and therapies.
Source: BMC Genomics - Latest articles - March 14, 2014 Category: Genetics & Stem Cells Authors: Man MaSantosh AtanurTimothy AitmanAnne Kwitek Source Type: research

Associations of Pentraxin 3 with Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis.
CONCLUSIONS: In these apparently healthy adults, PTX3 was associated with CVD risk factors, subclinical CVD, CAC and incident coronary heart disease events independent of CRP and CVD risk factors. These results support the hypothesis that PTX3 reflects different aspects of inflammation than CRP and may provide additional insight into the development and progression of atherosclerosis. This article is protected by copyright. All rights reserved. PMID: 24628740 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 13, 2014 Category: Hematology Authors: Jenny NS, Blumenthal RS, Kronmal RA, Rotter JI, Siscovick DS, Psaty BM Tags: J Thromb Haemost Source Type: research

Associations of pentraxin 3 with cardiovascular disease: the Multi‐Ethnic Study of Atherosclerosis
ConclusionsIn these apparently healthy adults, PTX3 was associated with CVD risk factors, subclinical CVD, CAC and incident coronary heart disease events independently of CRP and CVD risk factors. These results support the hypothesis that PTX3 reflects different aspects of inflammation than CRP, and may provide additional insights into the development and progression of atherosclerosis.
Source: Journal of Thrombosis and Haemostasis - June 10, 2014 Category: Hematology Authors: N. S. Jenny, R. S. Blumenthal, R. A. Kronmal, J. I. Rotter, D. S. Siscovick, B. M. Psaty Tags: Original Article Source Type: research

Sudachitin, a polymethoxylated flavone, improves glucose and lipid metabolism by increasing mitochondrial biogenesis in skeletal muscle
Conclusions: Sudachitin may improve dyslipidemia and metabolic syndrome by improving energy metabolism. Furthermore, it also induces mitochondrial biogenesis to protect against metabolic disorders.
Source: BioMed Central - July 4, 2014 Category: Journals (General) Authors: Rie TsutsumiTomomi YoshidaYoshitaka NiiNaoki OkahisaShinya IwataMasao TsukayamaRei HashimotoYasuko TaniguchiHiroshi SakaueToshio HosakaEmi ShutoTohru Sakai Source Type: research

Sudachitin, a polymethoxylated flavone, improves glucose and lipid metabolism by increasing mitochondrial biogenesis in skeletal muscle.
CONCLUSIONS: Sudachitin may improve dyslipidemia and metabolic syndrome by improving energy metabolism. Furthermore, it also induces mitochondrial biogenesis to protect against metabolic disorders. PMID: 25114710 [PubMed - as supplied by publisher]
Source: Diabetes Metab - August 14, 2014 Category: Endocrinology Authors: Tsutsumi R, Yoshida T, Nii Y, Okahisa N, Iwata S, Tsukayama M, Hashimoto R, Taniguchi Y, Sakaue H, Hosaka T, Shuto E, Sakai T Tags: Nutr Metab (Lond) Source Type: research